To develop a cost-effective, individualised anti-TNF treatment strategy for patients with Crohn's disease which maximizes benefit and minimises harm.
The primary objective of this study is to investigate the mechanisms that underlie primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADRs) to anti-TNF drugs in patients with active luminal Crohn's disease.
Study Type: Observational
Actual Enrollment: 1750 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Investigation of the Clinical,Serological and Genetic Factors That Determine Primary Non-response, Loss of Response and Adverse Drug Reactions to Anti-TNF Drugs in Patients With Active Luminal Crohn's Disease
Study Start Date: March 2013
Primary Completion Date: July 30, 2017
Estimated Study Completion Date: July 30, 2019
|Date last updated at source||2017-12-05|
|Study type(s)||Observational study|
|Study start date||2013-03-01|
|Estimated primary completion date||2017-07-01|